Latest / Decera Clinical Education Oncology Podcast
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:
Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
Approval of ibrutinib/venetoclax combination therapy for patients with CLL
Key differences between zanubrutinib and acalabrutinib in the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.